Study of Trastuzumab Deruxtecan, Pembrolizumab, and Chemotherapy for HER2-Overexpressing Lung Cancer
This study is for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. You might be able to join if your cancer has high levels of a protein called HER2 and you haven't had prior treatment for advanced disease. The study is testing two different combinations of medicines: trastuzumab deruxtecan (T-DXd; Enhertu®) with pembrolizumab, or platinum-based chemotherapy (like cisplatin or carboplatin) with pembrolizumab. Researchers want to see how safe and effective these combinations are in slowing down cancer growth. The study aims to enroll 686 participants.
- Study design
- This is an interventional study with a planned enrollment of 686 participants. It compares two different drug combinations.
- What's involved
- You will need to sign consent forms before any screening or study procedures. The specific number of visits, tests, or procedures is not detailed in this record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from the date of randomization until radiographic disease progression or death, for up to approximately 54 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
At a glance
Conditions
Where it's being run
237 sites across 38 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression Free Survival by Blinded Independent Central ReviewFrom date of randomization to the date of radiographic disease progression or death due to any cause, up to approximately 54 months
PFS is defined as the time interval from the date of randomization to the date of radiographic disease progression or death due to any cause. Tumor response will be determined by BICR assessment of tumor scans using RECIST v1.1.